ATHE - Arrowhead Pharmaceuticals Moxian Iterum Therapeutics among premarket losers' pack

Iterum Therapeutics (ITRM) -41% after FDA identifies deficiencies in sulopenem NDA.Arrowhead Pharmaceuticals (ARWR) -23% after pausing mid-stage AROENaC1001 study in cystic fibrosis.Birks Group (BGI) -13%.Alterity Therapeutics (ATHE) -12%.Kintara Therapeutics (KTRA) -8%.Citius Pharmaceuticals (CTXR) -8%.Grom Social Enterprises (GROM) -6%.Verb Technology Company (VERB) -6%.TRxADE HEALTH (MEDS) -6%.Moxian (MOXC) -5%.Wunong Net Technology (WNW) -6%.Predictive Oncology (POAI) -5%.

For further details see:

Arrowhead Pharmaceuticals, Moxian, Iterum Therapeutics among premarket losers' pack